Table 1 Associations between hERG1 expression and molecular and clinicopathological parameters
From: hERG1 channel expression associates with molecular subtypes and prognosis in breast cancer
| Â | hERG1 score 0 | hERG1 score 1 | hERG1 score 2 | hERG1 score 3 | p value |
|---|---|---|---|---|---|
Molecular subtype | |||||
 Luminal A | 0 (0%) | 0 (0%) | 0 (0%) | 11 (100%) | 0.001* |
 Luminal B | 0 (0%) | 0 (0%) | 3 (33.3%) | 6 (66.7%) | |
 HER2+ | 0 (0%) | 2 (20%) | 3 (30%) | 5 (50%) | |
 Basal-like | 0 (0%) | 1 (10%) | 7 (70%) | 2 (20%) | |
Grading | |||||
 G1 | 0 (0%) | 0 (0%) | 0 (0%) | 6 (100%) | 0.020* |
 G2 | 0 (0%) | 0 (0%) | 0 (0%) | 6 (100%) | |
 G3 | 0 (0%) | 3 (10.7%) | 13 (46.4%) | 12 (42.9%) | |
TNM stage | |||||
 I | 0 (0%) | 1 (4.3%) | 7 (30.4%) | 15 (65.2%) | 0.071 |
 II | 0 (0%) | 1 (11.1%) | 5 (55.6%) | 3 (33.3%) | |
 III | 0 (0%) | 0 (0%) | 1 (14.3%) | 6 (85.7%) | |
 IV | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) | |
ER | |||||
 Negative | 0 (0%) | 3 (15.8%) | 9 (47.4%) | 7 (36.8%) | 0.008* |
 Positive | 0 (0%) | 0 (0%) | 4 (19.1%) | 17 (80.9%) | |
PgR | |||||
 Negative | 0 (0%) | 3 (12.5%) | 10 (41.7%) | 11 (45.8%) | 0.083 |
 Positive | 0 (0%) | 0 (0%) | 3 (18.7%) | 13 (81.2%) | |
HER2 | |||||
 Negative | 0 (0%) | 1 (7.7%) | 7 (53.8%) | 5 (38.5%) | 0.079 |
 Score 1 | 0 (0%) | 0 (0%) | 0 (0%) | 7 (100%) | |
 Score 2 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
 Score 3 | 0 (0%) | 2 (10%) | 6 (30%) | 12 (60%) | |
Ki67 | |||||
 ≤15% | 0 (0%) | 0 (0%) | 0 (0%) | 8 (100%) | 0.038* |
 >15% | 0 (0%) | 3 (9.4%) | 13 (40.6%) | 16 (50%) | |